ANVISA – Post-pandemic challenges and perspectives.

What is the purpose of registration submission guide, based on data from scientific literature?

Clinical research in Brazil – New horizons, new challenges

ANVISA has just published the new version of the Cadifa Manual, but what were the main changes?

Unraveling the Abbreviated Development Path

Publication of the Public Consultation for the review of RDC 200 - what is new?

NEW REGULATORY FRAMEWORK OF API

INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200

COVID-19: What facilities is ANVISA providing at this time of crisis?

Why are 24% of drug registrations still rejected?

Cannabis: challenges and opportunities

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?

Publication of the new API regulatory framework: what is essential to know?

What is important about the new regulatory framework for good manufacturing practices?

Cannabis for therapeutic uses: is this a new market?

DDCM: what are the points that generate the most demands at ANVISA (Part 2)?

New rules for outsourcing in the pharmaceutical industry: many possibilities!